A deal for Ventyx would help Lilly compete in the promising space. If Ventyx’s experimental pills pan out, they would add to ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
GlobalData on MSN
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...
Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma ...
The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...
Eli Lilly has announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, a biopharmaceutical ...
Shares of Ventyx Biosciences gained after The Wall Street Journal reported that the company is in advanced talks to be acquired by Eli Lilly for about $1 billion. Ventyx shares were up 5.2%, to $8.23, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback